{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:10:39Z","timestamp":1780920639538,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":60,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101164","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:55:39Z","timestamp":1772610939000},"page":"101164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of a gene expression panel for prognostic stratification in high-risk prostate cancer"],"prefix":"10.1016","volume":"47","author":[{"given":"Poliana Rom\u00e3o","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana","family":"Vilas Boas Caetano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Landim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruan","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Alves","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Guimar\u00e2es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia Moreira","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Srougi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Srougi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-3597","authenticated-orcid":false,"given":"Sabrina Thalita dos","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101164_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"713","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101164_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"686","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101164_bib0003","unstructured":"INCA. Estimativa 2023: incid\u00eancia de c\u00e2ncer no Brasil. Rio de Janeiro 2022. p. 160."},{"key":"10.1016\/j.ctarc.2026.101164_bib0004","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.3390\/ijms21145036","article-title":"Hereditary predisposition to prostate cancer: from genetics to clinical implications","volume":"2114","author":"Brand\u00e3o","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101164_bib0005","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"35022","author":"Thompson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101164_bib0006","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"714","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101164_bib0007","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"28011","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2026.101164_bib0008","first-page":"163","article-title":"Natural history of surgically treated high-risk prostate cancer","volume":"334","author":"Briganti","year":"2015","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101164_bib0009","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"714","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101164_bib0010","article-title":"Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer","author":"Liu","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ctarc.2026.101164_bib0011","first-page":"2717","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","author":"Sekhoacha","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.ctarc.2026.101164_bib0012","series-title":"Prostate cancer tissue-based biomarkers","author":"I","year":"2024"},{"key":"10.1016\/j.ctarc.2026.101164_bib0013","doi-asserted-by":"crossref","first-page":"683","DOI":"10.4149\/neo_2015_082","article-title":"Biomarkers for determination prostate cancer: implication for diagnosis and prognosis","volume":"625","author":"Ziaran","year":"2015","journal-title":"Neoplasma"},{"key":"10.1016\/j.ctarc.2026.101164_bib0014","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1200\/JCO.2007.15.6752","article-title":"Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy","volume":"2624","author":"Cheville","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101164_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15321819.2015.1116009","article-title":"Proteomic approaches for biomarker panels in cancer","volume":"371","author":"Tanase","year":"2016","journal-title":"J. Immunoass. Immunochem."},{"key":"10.1016\/j.ctarc.2026.101164_bib0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/03008880510030932","article-title":"Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens","volume":"216","author":"Epstein","year":"2005","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"10.1016\/j.ctarc.2026.101164_bib0017","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.ejca.2007.06.006","article-title":"PSA and other tissue kallikreins for prostate cancer detection","volume":"4313","author":"Stephan","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101164_bib0018","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1515\/hsz-2017-0322","article-title":"Mining human cancer datasets for kallikrein expression in cancer: the 'KLK-CANMAP' Shiny web tool","volume":"3999","author":"Wang","year":"2018","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ctarc.2026.101164_bib0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.biochi.2015.09.002","article-title":"The kallikrein-related peptidase family: dysregulation and functions during cancer progression","volume":"122","author":"Kryza","year":"2016","journal-title":"Biochimie"},{"key":"10.1016\/j.ctarc.2026.101164_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2478\/raon-2013-0053","article-title":"Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases KLK in female and male reproductive organ malignancies","volume":"474","author":"Schmitt","year":"2013","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101164_bib0021","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3325\/cmj.2020.61.450","article-title":"Kallikrein gene family as biomarkers for recurrent prostate cancer","volume":"615","author":"Boyukozer","year":"2020","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.ctarc.2026.101164_bib0022","first-page":"184","article-title":"The new human tissue kallikrein gene family: structure, function, and association to disease","volume":"222","author":"Yousef","year":"2001","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ctarc.2026.101164_bib0023","first-page":"2380","article-title":"Higher human kallikrein gene 4 KLK4 expression indicates poor prognosis of ovarian cancer patients","volume":"78","author":"Obiezu","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101164_bib0024","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/1878-0261.12587","article-title":"The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer","volume":"141","author":"Kryza","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101164_bib0025","first-page":"256","article-title":"Effects of kallikrein-related peptidase 14 gene inhibition by small interfering RNA in ovarian carcinoma cells","volume":"51","author":"Zhang","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ctarc.2026.101164_bib0026","doi-asserted-by":"crossref","first-page":"8911","DOI":"10.1021\/jacs.1c03950","article-title":"A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer","volume":"14323","author":"Lovell","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ctarc.2026.101164_bib0027","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1349-7006.2009.01450.x","article-title":"Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia","volume":"1013","author":"Mavridis","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ctarc.2026.101164_bib0028","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/pros.22667","article-title":"Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression","volume":"7311","author":"Mavridis","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.ctarc.2026.101164_bib0029","first-page":"467","article-title":"Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens","author":"V\u00e4\u00e4n\u00e4nen","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ctarc.2026.101164_bib0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/path.5675","article-title":"Modelling hereditary diffuse gastric cancer initiation using transgenic mouse-derived gastric organoids and single-cell sequencing","volume":"2543","author":"Dixon","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.ctarc.2026.101164_bib0031","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/CEJ.0000000000000824","article-title":"CDH1 hypermethylation: a potential molecular pathway for invasiveness in glioblastoma","volume":"331","author":"Belut","year":"2024","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.ctarc.2026.101164_bib0032","first-page":"704","article-title":"SPOP and cancer: a systematic review","volume":"103","author":"Clark","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101164_bib0033","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.ejca.2014.08.009","article-title":"Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer","volume":"5017","author":"Garc\u00eda-Flores","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101164_bib0034","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2015.10.031","article-title":"Genetic progression of high grade prostatic intraepithelial neoplasia to prostate cancer","volume":"695","author":"Jung","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101164_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12881-019-0923-7","article-title":"Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis","volume":"201","author":"Sun","year":"2019","journal-title":"BMC. Med. Genet."},{"key":"10.1016\/j.ctarc.2026.101164_bib0036","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12032-018-1212-6","article-title":"Association of ERG\/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer","volume":"3512","author":"Mehra","year":"2018","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101164_bib0037","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/pcan.2016.11","article-title":"MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor","volume":"19","author":"Genitsch","year":"2016","journal-title":"Prostate Cancer Prostatic. Dis."},{"key":"10.1016\/j.ctarc.2026.101164_bib0038","series-title":"Prostate cancer [Internet]","article-title":"MUCIN 1 in prostate cancer","author":"Kapoor","year":"2021"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101164_bib0039","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/156800907780618338","article-title":"MUC1 is a promising therapeutic target for prostate cancer therapy","volume":"7","author":"Li","year":"2007","journal-title":"Curr. Cancer Drug Targets."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101164_bib0041","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/apm.13117","article-title":"Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer","volume":"129","author":"Stinnesbeck","year":"2021","journal-title":"APMIS"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101164_bib0042","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3390\/biom12111617","article-title":"EZH2 as a prognostic factor and its immune implication with molecular characterization in prostate cancer: an integrated multi-omics in silico analysis","volume":"12","author":"Du","year":"2022","journal-title":"Biomolecules."},{"key":"10.1016\/j.ctarc.2026.101164_bib0043","article-title":"EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway","author":"Yi","year":"2025","journal-title":"J. Clin. Invest."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:39:52Z","timestamp":1780918792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":42,"alternative-id":["S2468294226000754"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101164","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of a gene expression panel for prognostic stratification in high-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101164"}}